Macrophage signaling in HIV-1 infection

Retrovirology

Volumn 7, Issue , 2010, Pages

  Herbein, Georges ^a   Gras, Gabriel ^b   Khan, Kashif A ^a   Abbas, Wasim ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b CEA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESSORY PROTEIN; CHEMOKINE RECEPTOR; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEF PROTEIN; REGULATOR PROTEIN; STAT PROTEIN; STRUCTURAL PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VPR PROTEIN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRULENCE FACTOR; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

APOPTOSIS; CELL COMMUNICATION; DISEASE CARRIER; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LENTIVIRINAE; LONG TERMINAL REPEAT; MACROPHAGE; MICROGLIA; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TRANSPORT; REVIEW; T LYMPHOCYTE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSCRIPTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MACROPHAGE ACTIVATION; PATHOGENICITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRULENCE FACTORS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77950634929     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-34     Document Type: Review

References (199)

1. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 2009, 6:51. 10.1186/1742-4690-6-51, 2697150, 19486514.
2. Foster JL, Garcia JV. HIV-1 Nef: at the crossroads. Retrovirology 2008, 5:84. 10.1186/1742-4690-5-84, 2563024, 18808677.
3. Aiken C, Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995, 69:5048-5056. 189322, 7541845.
4. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644. 10.1038/385640a0, 9024663.
5. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176:287-292. 10.1084/jem.176.1.287, 2119288, 1613462.
6. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994, 179:101-113. 10.1084/jem.179.1.101, 2191317, 8270859.
7. Lama J, Mangasarian A, Trono D. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 1999, 9:622-631. 10.1016/S0960-9822(99)80284-X, 10375528.
8. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996, 2:338-342. 10.1038/nm0396-338, 8612235.
9. Fujii Y, Otake K, Tashiro M, Adachi A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett 1996, 393:93-96. 10.1016/0014-5793(96)00859-9, 8804432.
10. Brigino E, Haraguchi S, Koutsonikolis A, Cianciolo GJ, Owens U, Good RA, Day NK. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc Natl Acad Sci USA 1997, 94:3178-3182. 10.1073/pnas.94.7.3178, 20342, 9096366.
11. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006, 7:302-310. 10.1038/ni1302, 16429138.
12. Tobiume M, Fujinaga K, Suzuki S, Komoto S, Mukai T, Ikuta K. Extracellular Nef protein activates signal transduction pathway from Ras to mitogen-activated protein kinase cascades that leads to activation of human immunodeficiency virus from latency. AIDS Res Hum Retroviruses 2002, 18:461-467. 10.1089/088922202753614227, 11958689.
13. Varin A, Manna SK, Quivy V, Decrion AZ, Van Lint C, Herbein G, Aggarwal BB. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem 2003, 278:2219-2227. 10.1074/jbc.M209622200, 12419805.
14. Alessandrini L, Santarcangelo AC, Olivetta E, Ferrantelli F, d'Aloja P, Pugliese K, Pelosi E, Chelucci C, Mattia G, Peschle C, Verani P, Federico M. T-tropic human immunodeficiency virus (HIV) type 1 Nef protein enters human monocyte-macrophages and induces resistance to HIV replication: a possible mechanism of HIV T-tropic emergence in AIDS. J Gen Virol 2000, 81:2905-2917.
15. Quaranta MG, Camponeschi B, Straface E, Malorni W, Viora M. Induction of interleukin-15 production by HIV-1 nef protein: a role in the proliferation of uninfected cells. Exp Cell Res 1999, 250:112-121. 10.1006/excr.1999.4494, 10388525.
16. Quaranta MG, Mattioli B, Spadaro F, Straface E, Giordani L, Ramoni C, Malorni W, Viora M. HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells. FASEB J 2003, 17:2025-2036. 10.1096/fj.03-0272com, 14597672.
17. Kuster H, Opravil M, Ott P, Schlaepfer E, Fischer M, Gunthard HF, Luthy R, Weber R, Cone RW. Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. Am J Pathol 2000, 156:1973-1986. 1850084, 10854220.
18. Soudeyns H, Rebai N, Pantaleo GP, Ciurli C, Boghossian T, Sekaly RP, Fauci AS. The T cell receptor V beta repertoire in HIV-1 infection and disease. Semin Immunol 1993, 5:175-185. 10.1006/smim.1993.1021, 8102262.
19. Olivetta E, Percario Z, Fiorucci G, Mattia G, Schiavoni I, Dennis C, Jager J, Harris M, Romeo G, Affabris E, Federico M. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol 2003, 170:1716-1727.
20. Federico M, Percario Z, Olivetta E, Fiorucci G, Muratori C, Micheli A, Romeo G, Affabris E. HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 2001, 98:2752-2761. 10.1182/blood.V98.9.2752, 11675348.
21. Percario Z, Olivetta E, Fiorucci G, Mangino G, Peretti S, Romeo G, Affabris E, Federico M. Human immunodeficiency virus type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery. J Leukoc Biol 2003, 74:821-832. 10.1189/jlb.0403161, 12960275.
22. Mangino G, Percario ZA, Fiorucci G, Vaccari G, Manrique S, Romeo G, Federico M, Geyer M, Affabris E. In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release of beta interferon. J Virol 2007, 81:2777-2791. 10.1128/JVI.01640-06, 1865981, 17182689.
23. Schrager JA, Der Minassian V, Marsh JW. HIV Nef increases T cell ERK MAP kinase activity. J Biol Chem 2002, 277:6137-6142. 10.1074/jbc.M107322200, 11726657.
24. Hiscott J, Pitha P, Genin P, Nguyen H, Heylbroeck C, Mamane Y, Algarte M, Lin R. Triggering the interferon response: the role of IRF-3 transcription factor. J Interferon Cytokine Res 1999, 19:1-13. 10.1089/107999099314360, 10048763.
25. Sato M, Tanaka N, Hata N, Oda E, Taniguchi T. Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett 1998, 425:112-116. 10.1016/S0014-5793(98)00210-5, 9541017.
26. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998, 17:1087-1095. 10.1093/emboj/17.4.1087, 1170457, 9463386.
27. Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B. Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology 2009, 6:118. 10.1186/1742-4690-6-118, 2805609, 20030845.
28. Herbein G, Varin A, Larbi A, Fortin C, Mahlknecht U, Fulop T, Aggarwal BB. Nef and TNFalpha are coplayers that favor HIV-1 replication in monocytic cells and primary macrophages. Curr HIV Res 2008, 6:117-129. 10.2174/157016208783884985, 18336259.
29. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003, 424:213-219. 10.1038/nature01749, 12853962.
30. Mahlknecht U, Will J, Varin A, Hoelzer D, Herbein G. Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 2004, 173:3979-3990.
31. Jones KA. Tat and the HIV-1 promoter. Curr Opin Cell Biol 1993, 5:461-468. 10.1016/0955-0674(93)90012-F, 8352964.
32. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 1999, 274:28837-28840. 10.1074/jbc.274.41.28837, 10506122.
33. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993, 67:277-287.
34. Noonan D, Albini A. From the outside in: extracellular activities of HIV Tat. Adv Pharmacol 2000, 48:229-250. full_text, 10987093.
35. Gautier VW, Gu L, O'Donoghue N, Pennington S, Sheehy N, Hall WW. In vitro nuclear interactome of the HIV-1 Tat protein. Retrovirology 2009, 6:47. 10.1186/1742-4690-6-47, 2702331, 19454010.
36. Chang HK, Gallo RC, Ensoli B. Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein. J Biomed Sci 1995, 2:189-202. 10.1007/BF02253380, 11725056.
37. Albini A, Benelli R, Giunciuglio D, Cai T, Mariani G, Ferrini S, Noonan DM. Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem 1998, 273:15895-15900. 10.1074/jbc.273.26.15895, 9632634.
38. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000, 97:11466-11471. 10.1073/pnas.97.21.11466, 17223, 11027346.
39. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006, 9:917-924. 10.1038/nn1715, 16732273.
40. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 1996, 156:1638-1645.
41. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. J Immunol 1996, 157:974-977.
42. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318. 10.1126/science.1110647, 15831717.
43. Power C, McArthur JC, Nath A, Wehrly K, Mayne M, Nishio J, Langelier T, Johnson RT, Chesebro B. Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol 1998, 72:9045-9053. 110321, 9765449.
44. Puri RK, Aggarwal BB. Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line. Cancer Res 1992, 52:3787-3790.
45. Rautonen J, Rautonen N, Martin NL, Wara DW. HIV type 1 Tat protein induces immunoglobulin and interleukin 6 synthesis by uninfected peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1994, 10:781-785.
46. Sastry KJ, Reddy HR, Pandita R, Totpal K, Aggarwal BB. HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. J Biol Chem 1990, 265:20091-20093.
47. Puri RK, Leland P, Aggarwal BB. Constitutive expression of human immunodeficiency virus type 1 tat gene inhibits interleukin 2 and interleukin 2 receptor expression in a human CD4+ T lymphoid (H9) cell line. AIDS Res Hum Retroviruses 1995, 11:31-40. 10.1089/aid.1995.11.31, 7734194.
48. Husain SR, Leland P, Aggarwal BB, Puri RK. Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type 1 tat gene. AIDS Res Hum Retroviruses 1996, 12:1349-1359. 10.1089/aid.1996.12.1349, 8891114.
49. Lotz M, Clark-Lewis I, Ganu V. HIV-1 transactivator protein Tat induces proliferation and TGF beta expression in human articular chondrocytes. J Cell Biol 1994, 124:365-371. 10.1083/jcb.124.3.365, 2119928, 8294518.
50. Herbein G, Khan KA. Is HIV infection a TNF receptor signalling-driven disease?. Trends Immunol 2008, 29:61-67. 10.1016/j.it.2007.10.008, 18178131.
51. Kumar A, Manna SK, Dhawan S, Aggarwal BB. HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1. J Immunol 1998, 161:776-781.
52. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993, 67:277-287. 237361, 8416373.
53. Nath A, Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 1998, 54:19-33. 10.1016/S0301-0082(97)00053-1, 9460791.
54. Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006, 3:28. 10.1186/1742-4690-3-28, 1513597, 16712719.
55. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009, 27:119-145. 10.1146/annurev.immunol.021908.132528, 19302036.
56. Minghetti L, Levi G. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998, 54:99-125. 10.1016/S0301-0082(97)00052-X, 9460796.
57. Streit WJ. Microglia and the response to brain injury. Ernst Schering Res Found Workshop 2002, 11-24.
58. Sheng WS, Hu S, Hegg CC, Thayer SA, Peterson PK. Activation of human microglial cells by HIV-1 gp41 and Tat proteins. Clin Immunol 2000, 96:243-251. 10.1006/clim.2000.4905, 10964543.
59. Sawaya BE, Thatikunta P, Denisova L, Brady J, Khalili K, Amini S. Regulation of TNFalpha and TGFbeta-1 gene transcription by HIV-1 Tat in CNS cells. J Neuroimmunol 1998, 87:33-42. 10.1016/S0165-5728(98)00044-7, 9670843.
60. Polazzi E, Levi G, Minghetti L. Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures. J Neuropathol Exp Neurol 1999, 58:825-831. 10.1097/00005072-199908000-00005, 10446807.
61. De Simone R, Ajmone-Cat MA, Minghetti L. Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction. Mol Neurobiol 2004, 29:197-212. 10.1385/MN:29:2:197, 15126686.
62. Rosenstiel P, Lucius R, Deuschl G, Sievers J, Wilms H. From theory to therapy: implications from an in vitro model of ramified microglia. Microsc Res Tech 2001, 54:18-25. 10.1002/jemt.1116, 11526952.
63. Dollard SC, James HJ, Sharer LR, Epstein LG, Gelbard HA, Dewhurst S. Activation of nuclear factor kappa B in brains from children with HIV-1 encephalitis. Neuropathol Appl Neurobiol 1995, 21:518-528. 10.1111/j.1365-2990.1995.tb01098.x, 8745241.
64. Rostasy K, Monti L, Yiannoutsos C, Wu J, Bell J, Hedreen J, Navia BA. NFkappaB activation, TNF-alpha expression, and apoptosis in the AIDS-Dementia-Complex. J Neurovirol 2000, 6:537-543. 10.3109/13550280009091954, 11175326.
65. Nicolini A, Ajmone-Cat MA, Bernardo A, Levi G, Minghetti L. Human immunodeficiency virus type-1 Tat protein induces nuclear factor (NF)-kappaB activation and oxidative stress in microglial cultures by independent mechanisms. J Neurochem 2001, 79:713-716. 10.1046/j.1471-4159.2001.00568.x, 11701774.
66. Bruce-Keller AJ, Barger SW, Moss NI, Pham JT, Keller JN, Nath A. Pro-inflammatory and pro-oxidant properties of the HIV protein Tat in a microglial cell line: attenuation by 17 beta-estradiol. J Neurochem 2001, 78:1315-1324. 10.1046/j.1471-4159.2001.00511.x, 11579140.
67. Bowie A, O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000, 59:13-23. 10.1016/S0006-2952(99)00296-8, 10605930.
68. Hegg CC, Hu S, Peterson PK, Thayer SA. Beta-chemokines and human immunodeficiency virus type-1 proteins evoke intracellular calcium increases in human microglia. Neuroscience 2000, 98:191-199. 10.1016/S0306-4522(00)00101-9, 10858625.
69. Patrizio M, Colucci M, Levi G. Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures. J Neurochem 2001, 77:399-407. 10.1046/j.1471-4159.2001.00249.x, 11299302.
70. Aloisi F, De Simone R, Columba-Cabezas S, Levi G. Opposite effects of interferon-gamma and prostaglandin E2 on tumor necrosis factor and interleukin-10 production in microglia: a regulatory loop controlling microglia pro- and anti-inflammatory activities. J Neurosci Res 1999, 56:571-580. 10.1002/(SICI)1097-4547(19990615)56:6<571::AID-JNR3>3.0.CO;2-P, 10374812.
71. Aloisi F, Penna G, Cerase J, Menendez Iglesias B, Adorini L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J Immunol 1997, 159:1604-1612.
72. Caggiano AO, Kraig RP. Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1beta production. J Neurochem 1999, 72:565-575. 10.1046/j.1471-4159.1999.0720565.x, 2807136, 9930728.
73. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005, 8:752-758. 10.1038/nn1472, 15895084.
74. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, Levi G. Prostaglandin E2 downregulates inducible nitric oxide synthase expression in microglia by increasing cAMP levels. Adv Exp Med Biol 1997, 433:181-184.
75. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, Levi G. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1997, 19:152-160. 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2, 9034831.
76. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 2007, 4:e124. 10.1371/journal.pmed.0040124, 1851623,1851623, 17425404.
77. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001, 2:599-609. 10.1038/35085068, 11483993.
78. Kettenmann H, Hoppe D, Gottmann K, Banati R, Kreutzberg G. Cultured microglial cells have a distinct pattern of membrane channels different from peritoneal macrophages. J Neurosci Res 1990, 26:278-287. 10.1002/jnr.490260303, 1697905.
79. Korotzer AR, Cotman CW. Voltage-gated currents expressed by rat microglia in culture. Glia 1992, 6:81-88. 10.1002/glia.440060202, 1328052.
80. Visentin S, Agresti C, Patrizio M, Levi G. Ion channels in rat microglia and their different sensitivity to lipopolysaccharide and interferon-gamma. J Neurosci Res 1995, 42:439-451. 10.1002/jnr.490420402, 8568930.
81. Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, Gras G. Characterization of human monocyte-derived microglia-like cells. Glia 2006, 54:183-192. 10.1002/glia.20372, 16807899.
82. Visentin S, Levi G. Protein kinase C involvement in the resting and interferon-gamma-induced K+ channel profile of microglial cells. J Neurosci Res 1997, 47:233-241. 10.1002/(SICI)1097-4547(19970201)47:3<233::AID-JNR1>3.0.CO;2-J, 9039645.
83. Visentin S, Renzi M, Levi G. Altered outward-rectifying K(+) current reveals microglial activation induced by HIV-1 Tat protein. Glia 2001, 33:181-190. 10.1002/1098-1136(200103)33:3<181::AID-GLIA1017>3.0.CO;2-Q, 11241736.
84. Cheeseman CI. Molecular mechanisms involved in the regulation of amino acid transport. Prog Biophys Mol Biol 1991, 55:71-84. 10.1016/0079-6107(91)90001-9, 1871316.
85. Gras G, Porcheray F, Samah B, Leone C. The glutamate-glutamine cycle as an inducible, protective face of macrophage activation. J Leukoc Biol 2006, 80:1067-1075. 10.1189/jlb.0306153, 16912070.
86. Porcheray F, Leone C, Samah B, Rimaniol AC, Dereuddre-Bosquet N, Gras G. Glutamate metabolism in HIV-infected macrophages: implications for the CNS. Am J Physiol Cell Physiol 2006, 291:C618-626. 10.1152/ajpcell.00021.2006, 16687472.
87. Rimaniol AC, Mialocq P, Clayette P, Dormont D, Gras G. Role of glutamate transporters in the regulation of glutathione levels in human macrophages. Am J Physiol Cell Physiol 2001, 281:C1964-1970.
88. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993, 43:2245-2252.
89. Emerman M. HIV-1, Vpr and the cell cycle. Curr Biol 1996, 6:1096-1103. 10.1016/S0960-9822(02)00676-0, 8805364.
90. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673. 10.1038/381667a0, 8649512.
91. Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D, Cohen EA. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998, 187:1103-1111. 10.1084/jem.187.7.1103, 2212198, 9529326.
92. Vodicka MA, Koepp DM, Silver PA, Emerman M. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998, 12:175-185. 10.1101/gad.12.2.175, 316441, 9436978.
93. Jacquot G, Le Rouzic E, David A, Mazzolini J, Bouchet J, Bouaziz S, Niedergang F, Pancino G, Benichou S. Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 2007, 4:84. 10.1186/1742-4690-4-84, 2211753, 18039376.
94. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994, 91:7311-7315. 10.1073/pnas.91.15.7311, 44389, 8041786.
95. Ogawa K, Shibata R, Kiyomasu T, Higuchi I, Kishida Y, Ishimoto A, Adachi A. Mutational analysis of the human immunodeficiency virus vpr open reading frame. J Virol 1989, 63:4110-4114. 251018, 2474678.
96. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman HE, Ratner L. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol 1992, 66:3925-3931. 241183, 1533883.
97. Balotta C, Lusso P, Crowley R, Gallo RC, Franchini G. Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages. J Virol 1993, 67:4409-4414. 237816, 8510229.
98. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 1994, 200:623-631. 10.1006/viro.1994.1225, 8178448.
99. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O'Connor MJ, Doms RW, Gonzalez-Scarano F. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 1999, 73:205-213. 103824, 9847323.
100. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998, 280:1880-1884. 10.1126/science.280.5371.1880, 9632380.
101. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 1998, 67:1-25. 10.1146/annurev.biochem.67.1.1, 9759480.
102. Bukrinsky M, Adzhubei A. Viral protein R of HIV-1. Rev Med Virol 1999, 9:39-49. 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3, 10371671.
103. Stewart SA, Poon B, Song JY, Chen IS. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 2000, 74:3105-3111. 10.1128/JVI.74.7.3105-3111.2000, 111809, 10708425.
104. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995, 69:6705-6711. 189580, 7474080.
105. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 1995, 69:6304-6313. 189529, 7666531.
106. Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 1995, 69:6859-6864. 189600, 7474100.
107. Sawaya BE, Khalili K, Mercer WE, Denisova L, Amini S. Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription. J Biol Chem 1998, 273:20052-20057. 10.1074/jbc.273.32.20052, 9685344.
108. Bartz SR, Rogel ME, Emerman M. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 1996, 70:2324-2331. 190074, 8642659.
109. Yao XJ, Mouland AJ, Subbramanian RA, Forget J, Rougeau N, Bergeron D, Cohen EA. Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J Virol 1998, 72:4686-4693. 109992, 9573232.
110. Watanabe N, Yamaguchi T, Akimoto Y, Rattner JB, Hirano H, Nakauchi H. Induction of M-phase arrest and apoptosis after HIV-1 Vpr expression through uncoupling of nuclear and centrosomal cycle in HeLa cells. Exp Cell Res 2000, 258:261-269. 10.1006/excr.2000.4908, 10896777.
111. Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, Metivier D, Lenoir C, Geuskens M, Vieira HL, Loeffler M, Belzacq AS, Briand JP, Zamzami N, Edelman L, Xie ZH, Reed JC, Roques BP, Kroemer G. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 2001, 193:509-519. 10.1084/jem.193.4.509, 2195906, 11181702.
112. Gummuluru S, Emerman M. Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J Virol 1999, 73:5422-5430. 112598, 10364289.
113. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995, 270:25564-25569. 10.1074/jbc.270.43.25564, 7592727.
114. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 2000, 275:35209-35214. 10.1074/jbc.M005197200, 10931842.
115. Varin A, Decrion AZ, Sabbah E, Quivy V, Sire J, Van Lint C, Roques BP, Aggarwal BB, Herbein G. Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. J Biol Chem 2005, 280:42557-42567. 10.1074/jbc.M502211200, 16243842.
116. Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Goldsmith MA. HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med 2001, 194:1407-1419. 10.1084/jem.194.10.1407, 2193684, 11714748.
117. Vazquez N, Greenwell-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE, Schubert U, Henklein P, Orenstein JM, Sporn MB, Wahl SM. Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. J Virol 2005, 79:4479-4491. 10.1128/JVI.79.7.4479-4491.2005, 1061522, 15767448.
118. Muthumani K, Hwang DS, Choo AY, Mayilvahanan S, Dayes NS, Thieu KP, Weiner DB. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 2005, 17:103-116. 10.1093/intimm/dxh190, 15611322.
119. Muthumani K, Kudchodkar S, Papasavvas E, Montaner LJ, Weiner DB, Ayyavoo V. HIV-1 Vpr regulates expression of beta chemokines in human primary lymphocytes and macrophages. J Leukoc Biol 2000, 68:366-372.
120. Muthumani K, Hwang DS, Dayes NS, Kim JJ, Weiner DB. The HIV-1 accessory gene vpr can inhibit antigen-specific immune function. DNA Cell Biol 2002, 21:689-695. 10.1089/104454902760330237, 12396612.
121. Herbein G, Keshav S, Collin M, Montaner LJ, Gordon S. HIV-1 induces tumour necrosis factor and IL-1 gene expression in primary human macrophages independent of productive infection. Clin Exp Immunol 1994, 95:442-449. 1535095, 7511077.
122. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815. 10.1126/science.270.5243.1811, 8525373.
123. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958. 10.1126/science.272.5270.1955, 8658171.
124. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148. 10.1016/S0092-8674(00)81313-6, 8674119.
125. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666. 10.1038/381661a0, 8649511.
126. Liu Y, Hao W, Letiembre M, Walter S, Kulanga M, Neumann H, Fassbender K. Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 2006, 26:12904-12913. 10.1523/JNEUROSCI.2531-06.2006, 17167081.
127. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158. 10.1016/S0092-8674(00)81314-8, 8674120.
128. Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication. Nature 1996, 382:767. 10.1038/382767a0, 8752270.
129. Wang J, Roderiquez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998, 72:7642-7647. 110028, 9696868.
130. Verani A, Gras G, Pancino G. Macrophages and HIV-1: dangerous liaisons. Mol Immunol 2005, 42:195-212. 10.1016/j.molimm.2004.06.020, 15488608.
131. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 2008, 5:111. 10.1186/1742-4690-5-111, 2633019, 19077194.
132. Bergamini A, Faggioli E, Bolacchi F, Gessani S, Cappannoli L, Uccella I, Demin F, Capozzi M, Cicconi R, Placido R, Vendetti S, Colizzi GM, Rocchi G. Enhanced production of tumor necrosis factor-alpha and interleukin-6 due to prolonged response to lipopolysaccharide in human macrophages infected in vitro with human immunodeficiency virus type 1. J Infect Dis 1999, 179:832-842. 10.1086/314662, 10068578.
133. Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, Natarajan V, Farrar WL. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 1991, 147:2892-2901.
134. Karsten V, Gordon S, Kirn A, Herbein G. HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor-alpha. Immunology 1996, 88:55-60. 10.1046/j.1365-2567.1996.d01-648.x, 1456460, 8707350.
135. Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989, 63:4404-4408. 251058, 2789293.
136. Choe W, Volsky DJ, Potash MJ. Induction of rapid and extensive beta-chemokine synthesis in macrophages by human immunodeficiency virus type 1 and gp120, independently of their coreceptor phenotype. J Virol 2001, 75:10738-10745. 10.1128/JVI.75.22.10738-10745.2001, 114655, 11602715.
137. Bailer RT, Lee B, Montaner LJ. IL-13 and TNF-alpha inhibit dual-tropic HIV-1 in primary macrophages by reduction of surface expression of CD4, chemokine receptors CCR5, CXCR4 and post-entry viral gene expression. Eur J Immunol 2000, 30:1340-1349. 10.1002/(SICI)1521-4141(200005)30:5<1340::AID-IMMU1340>3.0.CO;2-L, 10820380.
138. Faltynek CR, Finch LR, Miller P, Overton WR. Treatment with recombinant IFN-gamma decreases cell surface CD4 levels on peripheral blood monocytes and on myelomonocyte cell lines. J Immunol 1989, 142:500-508.
139. Montaner LJ, Herbein G, Gordon S. Regulation of macrophage activation and HIV replication. Adv Exp Med Biol 1995, 374:47-56.
140. Cotter RL, Zheng J, Che M, Niemann D, Liu Y, He J, Thomas E, Gendelman HE. Regulation of human immunodeficiency virus type 1 infection, beta-chemokine production, and CCR5 expression in CD40L-stimulated macrophages: immune control of viral entry. J Virol 2001, 75:4308-4320. 10.1128/JVI.75.9.4308-4320.2001, 114176, 11287580.
141. Herbein G, Montaner LJ, Gordon S. Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. J Virol 1996, 70:7388-7397. 190806, 8892857.
142. Herbein G, Gordon S. 55- and 75-kilodalton tumor necrosis factor receptors mediate distinct actions in regard to human immunodeficiency virus type 1 replication in primary human macrophages. J Virol 1997, 71:4150-4156. 191574, 9094699.
143. Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS. Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages. Virology 1993, 193:138-148. 10.1006/viro.1993.1110, 7679856.
144. Zaitseva M, Lee S, Lapham C, Taffs R, King L, Romantseva T, Manischewitz J, Golding H. Interferon gamma and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency virus type 1 infection. Blood 2000, 96:3109-3117.
145. Cremer I, Vieillard V, De Maeyer E. Retrovirally mediated IFN-beta transduction of macrophages induces resistance to HIV, correlated with up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression. J Immunol 2000, 164:1582-1587.
146. Hewson TJ, Logie JJ, Simmonds P, Howie SE. A CCR5-dependent novel mechanism for type 1 HIV gp120 induced loss of macrophage cell surface CD4. J Immunol 2001, 166:4835-4842.
147. Lane BR, Markovitz DM, Woodford NL, Rochford R, Strieter RM, Coffey MJ. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol 1999, 163:3653-3661.
148. Coffey MJ, Woffendin C, Phare SM, Strieter RM, Markovitz DM. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am J Physiol 1997, 272:L1025-1029.
149. Jiang Y, Jolly PE. Effect of beta-chemokines on human immunodeficiency virus type 1 replication, binding, uncoating, and CCR5 receptor expression in human monocyte-derived macrophages. J Hum Virol 1999, 2:123-132.
150. Capobianchi MR, Abbate I, Antonelli G, Turriziani O, Dolei A, Dianzani F. Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses 1998, 14:233-240. 10.1089/aid.1998.14.233, 9491913.
151. Ylisastigui L, Amzazi S, Bakri Y, Vizzavona J, Vita C, Gluckman JC, Benjouad A. Effect of RANTES on the infection of monocyte-derived primary macrophages by human immunodeficiency virus type 1 and type 2. Biomedicine & Pharmacotherapy 1998, 52:447-453.
152. Stantchev TS, Broder CC. Consistent and significant inhibition of human immunodeficiency virus type 1 envelope-mediated membrane fusion by beta-chemokines (RANTES) in primary human macrophages. J Infect Dis 2000, 182:68-78. 10.1086/315700, 10882583.
153. Moriuchi H, Moriuchi M, Fauci AS. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 1997, 158:3483-3491.
154. Wahl LM, Corcoran ML, Pyle SW, Arthur LO, Harel-Bellan A, Farrar WL. Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1. Proc Natl Acad Sci USA 1989, 86:621-625. 10.1073/pnas.86.2.621, 286524, 2536171.
155. Klasse PJ, Moore JP. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? . Virology 2004, 323:1-8.
156. Yi Y, Lee C, Liu QH, Freedman BD, Collman RG. Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: Implications for neuropathogenesis. J Neurovirol 2004, 10(Suppl 1):91-96.
157. Liu QH, Williams DA, McManus C, Baribaud F, Doms RW, Schols D, De Clercq E, Kotlikoff MI, Collman RG, Freedman BD. HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci USA 2000, 97:4832-4837. 10.1073/pnas.090521697, 18318, 10758170.
158. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, O'Brien WA, Verdin E. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998, 395:189-194. 10.1038/26026, 9744279.
159. Decrion AZ, Varin A, Estavoyer JM, Herbein G. CXCR4-Mediated T Cell Apoptosis in HIV infection. Journal of General Virology 2004, 85:1471-8. 10.1099/vir.0.79933-0, 15166430.
160. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 2003, 24:346-354. 10.1016/S0165-6147(03)00167-6, 12871667.
161. Del Corno M, Liu QH, Schols D, de Clercq E, Gessani S, Freedman BD, Collman RG. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 2001, 98:2909-2916. 10.1182/blood.V98.10.2909, 11698270.
162. Tomkowicz B, Lee C, Ravyn V, Cheung R, Ptasznik A, Collman RG. The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages. Blood 2006, 108:1145-1150. 10.1182/blood-2005-12-012815, 1895866, 16621960.
163. Lynch GW, Turville S, Carter B, Sloane AJ, Chan A, Muljadi N, Li S, Low L, Armati P, Raison R, Zoellner H, Williamson P, Cunningham A, Church WB. Marked differences in the structures and protein associations of lymphocyte and monocyte CD4: resolution of a novel CD4 isoform. Immunol Cell Biol 2006, 84:154-165. 10.1111/j.1440-1711.2005.01403.x, 16519733.
164. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S, Kim B. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 2008, 5:11. 10.1186/1742-4690-5-11, 2265748, 18237430.
165. Benkirane M, Jeang KT, Devaux C. The cytoplasmic domain of CD4 plays a critical role during the early stages of HIV infection in T-cells. Embo J 1994, 13:5559-5569. 395519, 7988553.
166. Briant L, Coudronniere N, Robert-Hebmann V, Benkirane M, Devaux C. Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection. J Immunol 1996, 156:3994-4004.
167. Briant L, Robert-Hebmann V, Acquaviva C, Pelchen-Matthews A, Marsh M, Devaux C. The protein tyrosine kinase p56lck is required for triggering NF-kappaB activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4. J Virol 1998, 72:6207-6214. 110439, 9621091.
168. Chirmule N, Kalyanaraman VS, Pahwa S. Signals transduced through the CD4 molecule on T lymphocytes activate NF-kappa B. Biochem Biophys Res Commun 1994, 203:498-505. 10.1006/bbrc.1994.2210, 7915519.
169. Popik W, Pitha PM. Binding of human immunodeficiency virus type 1 to CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent pathway. Mol Cell Biol 1996, 16:6532-6541. 231655, 8887682.
170. Popik W, Hesselgesser JE, Pitha PM. Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway. J Virol 1998, 72:6406-6413. 109793, 9658081.
171. Schmid-Antomarchi H, Benkirane M, Breittmayer V, Husson H, Ticchioni M, Devaux C, Rossi B. HIV induces activation of phosphatidylinositol 4-kinase and mitogen-activated protein kinase by interacting with T cell CD4 surface molecules. Eur J Immunol 1996, 26:717-720. 10.1002/eji.1830260331, 8605943.
172. Biard-Piechaczyk M, Robert-Hebmann V, Richard V, Roland J, Hipskind RA, Devaux C. Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology 2000, 268:329-344. 10.1006/viro.1999.0151, 10704341.
173. Duong LT, Rodan GA. PYK2 is an adhesion kinase in macrophages, localized in podosomes and activated by beta(2)-integrin ligation. Cell Motil Cytoskeleton 2000, 47:174-188. 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N, 11056520.
174. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, Thompson DA, Schlessinger J, Littman DR. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 1997, 186:1793-1798. 10.1084/jem.186.10.1793, 2199136, 9362541.
175. Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP, Schlessinger J. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci USA 2003, 100:10740-10745. 10.1073/pnas.1834348100, 196873, 12960403.
176. Herbein G, Coaquette A, Perez-Bercoff D, Pancino G. Macrophage activation and HIV infection: can the Trojan horse turn into a fortress?. Curr Mol Med 2002, 2:723-738. 10.2174/1566524023361844, 12462393.
177. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995, 1:129-134. 10.1038/nm0295-129, 7585008.
178. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Greenwald DR, Herzenberg LA. HIV type 1 Tat protein enhances activation-but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals. Int Immunol 1997, 9:835-841. 10.1093/intimm/9.6.835, 9199966.
179. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331-340. 10.1084/jem.175.2.331, 2119133, 1346269.
180. Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS, Pahwa S. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 1993, 82:3392-3400.
181. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001, 410:834-838. 10.1038/35071111, 11298454.
182. Yoon K, Jeong JG, Kim S. Stable expression of human immunodeficiency virus type 1 Nef confers resistance against Fas-mediated apoptosis. AIDS Res Hum Retroviruses 2001, 17:99-104. 10.1089/08892220150217184, 11177389.
183. Mahlknecht U, Herbein G. Macrophages and T-cell apoptosis in HIV infection: a leading role for accessory cells?. Trends Immunol 2001, 22:256-260. 10.1016/S1471-4906(01)01898-1, 11323283.
184. Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O'Brien WA, Herbein G. Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence. J Immunol 2000, 165:6437-6446.
185. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996, 70:199-206. 189805, 8523526.
186. Badley AD, Dockrell D, Simpson M, Schut R, Lynch DH, Leibson P, Paya CV. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997, 185:55-64. 10.1084/jem.185.1.55, 2196110, 8996241.
187. Gendelman HE, Orenstein JM, Baca LM, Weiser B, Burger H, Kalter DC, Meltzer MS. The macrophage in the persistence and pathogenesis of HIV infection. Aids 1989, 3:475-495.
188. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377:348-351. 10.1038/377348a0, 7566090.
189. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83:793-802. 10.1016/0092-8674(95)90192-2, 8521496.
190. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988, 85:289-291. 10.1016/0002-9343(88)90576-1, 3414726.
191. Poonia B, Pauza CD, Salvato MS. Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology 2009, 6:91. 10.1186/1742-4690-6-91, 2772842, 19832988.
192. Galea I, Palin K, Newman TA, Van Rooijen N, Perry VH, Boche D. Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia 2005, 49:375-384. 10.1002/glia.20124, 15538754.
193. Blair PJ, Boise LH, Perfetto SP, Levine BL, McCrary G, Wagner KF, St Louis DC, Thompson CB, Siegel JN, June CH. Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. J Clin Immunol 1997, 17:234-246. 10.1023/A:1027310612323, 9168404.
194. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999, 96:8212-8216. 10.1073/pnas.96.14.8212, 22214, 10393974.
195. Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW. Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 2000, 6(Suppl 1):S82-85.
196. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, Lackner AA, Janoff EN, Wang R, Fisher D, Stevenson M. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999, 5:997-103. 10.1038/12433, 10470075.
197. Smit TK, Wang B, Ng T, Osborne R, Brew B, Saksena NK. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): evidence for neurotropic HIV variants. Virology 2001, 279:509-526. 10.1006/viro.2000.0681, 11162807.
198. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989, 86:5974-5978. 10.1073/pnas.86.15.5974, 297754, 2762307.
199. Antoni BA, Sabbatini P, Rabson AB, White E. Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection. J Virol 1995, 69:2384-2392. 188911, 7884884.